Focus on Anticoagulation Care

Back to articles

Bleeding risk higher with dabigatran than warfarin

KEY POINT

Compared with warfarin, dabigatran (Pradaxa—Boehringer Ingelheim) was associated with a higher risk of bleeding, including major and gastrointestinal (GI) bleeding, especially in high-risk patients, according to a study of Medicare beneficiaries.

SOURCES

Hernandez I et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175:18–24.  

Redberg RF. The importance of postapproval data for dabigatran. JAMA Intern Med. 2015;175:25.